Agile Therapeutics Inc (NASDAQ:AGRX) shares were down 5.6% on Thursday . The stock traded as low as $0.85 and last traded at $0.84. Approximately 20,159 shares changed hands during trading, a decline of 99% from the average daily volume of 1,633,336 shares. The stock had previously closed at $0.89.
Several research analysts recently weighed in on AGRX shares. ValuEngine raised Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. HC Wainwright set a $4.00 target price on Agile Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $4.00.
The firm has a market cap of $12.60 million, a P/E ratio of -0.88 and a beta of 1.43.
Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. On average, equities research analysts anticipate that Agile Therapeutics Inc will post -0.61 EPS for the current fiscal year.
In other news, insider Life Sciences Maste Perceptive sold 298,628 shares of the company’s stock in a transaction on Thursday, July 26th. The stock was sold at an average price of $0.30, for a total transaction of $89,588.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.30% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in AGRX. Renaissance Technologies LLC lifted its holdings in shares of Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the last quarter. Finally, A.R.T. Advisors LLC lifted its holdings in shares of Agile Therapeutics by 82.3% during the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the last quarter. 52.00% of the stock is owned by institutional investors and hedge funds.
Agile Therapeutics Company Profile (NASDAQ:AGRX)
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Read More: Average Daily Trade Volume Explained
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.